- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Oct
Sep
Jul
- Dr. Reddy’s Q1 FY14 Financial Results : Q1 FY14 Revenues at ₹28.4 billion
- Dr. Reddy’s Q1 FY14 Financial Results : Q1 FY14 Revenues at ₹28.4 billion
- Dr. Reddy’s announces the Launch of Donepezil Hydrochloride Tablets, 23 mg
- Dr. Reddy’s announces the Launch of Decitabine for Injection
- Earnings call slated for July 30, 6.30 PM IST / 9.00 AM EDT*
Jun
May
- Dr. Reddy’s Q4 & FY13 Financial Results: Highest ever Quarterly Performance FY13 Revenues at ₹116.3 billion (YoY growth of 26%)
- Dr. Reddy’s Q4 & FY13 Financial Results: Highest ever Quarterly Performance FY13 Revenues at ₹116.3 billion (YoY growth of 26%)
- Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection
Apr
- Dr. Reddy's to release Q4 & Full Year FY13 results on May 14, 2013 Earnings call slated for May 14, 6.30 PM IST / 9.00 AM EDT
- Dr. Reddy’s announces the relocation of their North America headquarters and establishment of a R&D Center in Princeton, NJ, USA
- Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection
- Dr. Reddy’s appoints GV Prasad as Chairman and Satish Reddy as Vice-Chairman of the Company
Feb
- Dr. Reddy’s holds 98.6% of the shares in OctoPlus after the Post Closing Acceptance Period
- Dr. Reddy’s Q3 & 9 months FY13 Financial Results: Q3 FY13 Revenues at ₹28.7 billion (YoY growth of 23%)
- Dr. Reddy’s Q3 & 9 months FY13 Financial Results: Q3 FY13 Revenues at ₹28.7 billion (YoY growth of 23%)
- Dr. Reddy’s declares Offer for OctoPlus unconditional
- Dr. Reddy's to release Q3 FY13 results on February 14, 2013
